Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Sales | 6,004 | 5,651 | 5,761 | 5,296 | 5,198 |
| Cost of Goods | 2,115 | 1,937 | 1,967 | 1,742 | 1,539 |
| Gross Profit | 3,889 | 3,714 | 3,794 | 3,554 | 3,659 |
| Operating Expenses | 3,634 | 4,678 | 5,074 | 4,785 | 4,251 |
| Operating Income | 370 | -27 | -313 | -489 | -53 |
| Other Income | -138 | -73 | -94 | -105 | -122 |
| Pre-tax Income | 232 | -100 | -407 | -594 | -175 |
| Income Tax | 10 | 24 | 2 | 45 | 9 |
| Net Income Continuous | 222 | -124 | -409 | -639 | -184 |
| Net Income | $222 | $-124 | $-409 | $-639 | $-184 |
| EPS Basic Total Ops | 1,199.40 | -749.63 | -2,398.80 | -4,047.98 | -1,049.48 |
| EPS Basic Continuous Ops | 1,164.98 | -739.49 | -2,443.00 | -3,926.68 | -1,101.25 |
| EPS Diluted Total Ops | 1,199.40 | -749.63 | -2,398.80 | -4,047.98 | -1,049.48 |
| EPS Diluted Continuous Ops | 1,164.98 | -739.49 | -2,443.00 | -3,926.68 | -1,101.25 |
| EBITDA(a) | $1,142 | $679 | $334 | $133 | $546 |